TScan Therapeutics (NASDAQ:TCRX - Free Report) had its price objective decreased by Needham & Company LLC from $11.00 to $9.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Several other equities research analysts have also recently commented on TCRX. Wedbush reaffirmed an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Monday, December 23rd. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, TScan Therapeutics presently has an average rating of "Buy" and a consensus price target of $9.20.
View Our Latest Research Report on TScan Therapeutics
TScan Therapeutics Price Performance
Shares of NASDAQ TCRX traded down $0.10 during midday trading on Wednesday, hitting $1.98. The stock had a trading volume of 207,206 shares, compared to its average volume of 312,081. The company has a market capitalization of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. The stock has a 50 day simple moving average of $2.41 and a 200-day simple moving average of $3.99. TScan Therapeutics has a 1 year low of $1.82 and a 1 year high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.43 million. On average, sell-side analysts expect that TScan Therapeutics will post -1.12 EPS for the current fiscal year.
Institutional Investors Weigh In On TScan Therapeutics
A number of institutional investors have recently modified their holdings of TCRX. Checkpoint Capital L.P. acquired a new stake in shares of TScan Therapeutics in the third quarter valued at $4,110,000. abrdn plc grew its stake in shares of TScan Therapeutics by 137.8% in the fourth quarter. abrdn plc now owns 883,704 shares of the company's stock valued at $2,686,000 after buying an additional 512,049 shares in the last quarter. State Street Corp grew its stake in shares of TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company's stock valued at $3,767,000 after buying an additional 148,414 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock valued at $851,000 after buying an additional 145,731 shares in the last quarter. Finally, Lynx1 Capital Management LP grew its stake in shares of TScan Therapeutics by 2.5% in the fourth quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock valued at $16,286,000 after buying an additional 132,747 shares in the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.
TScan Therapeutics Company Profile
(
Get Free Report)
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Further Reading
Before you consider TScan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.
While TScan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
